Interruption of mitochondrial symbiosis is associated with the development of osteoporosis by Haoling Zhang, Haoling Zhang, Haoling Zhang, Rui Zhao, Xuemei Wang, Yaqian Qi, Doblin Sandai, Wei Wang, Zhijing Song, Zhijing Song, Qiudong Liang

“…Nevertheless, the controlled release of mitochondrial components into the cytoplasm can initiate cell death, activate innate immunity, and provoke inflammation. …”
Get full text

Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failur... by Wen-xiong Xu, Hong-liang He, Shun-wen Pan, Yuan-li Chen, Mei-ling Zhang, Shu Zhu, Zhi-liang Gao, Liang Peng, Jian-guo Li

“…The endpoint outcomes were death and unfavorable outcome (need for liver transplantation or death). …”
Get full text

Aflatoxin B1 impairs the growth and development of chicken PGCs through oxidative stress and mitochondrial dysfunction by Ying-Jie Niu, Jun Wu, Wenjie Ren, Guangzheng Liu, Gaoyuan Wu, Yixiu Peng, Dan Zheng, Kai Jin, Qisheng Zuo, Guohui Li, Wei Han, Xiang-Shun Cui, Guohong Chen, Bichun Li

“…Inhibiting NRF2 exacerbated oxidative stress and cell death in PGCs, suggesting NRF2 upregulation plays a protective role under AFB1 regulation. …”
Get full text

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial by Łukasz Kuncman, Jacek Fijuth, Damian Tworek, Ewa Sierko, Paweł Cisek, Michał Masłowski, Maja Lisik-Habib, Magdalena Orzechowska, Katarzyna Galwas-Kliber, Adam Antczak, Izabela Chmielewska, Barbara Ziółkowska, Marta Kurczewska-Michalak, Wojciech Kuźnicki, Nina Jędrzejczak, Kinga Ranoszek, Mateusz Bilski

“…Abstract Background The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. …”
Get full text

Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weigh... by Jing Cheng, Yang Du, Karl Sylvester, Shaoping Wu, Suixin Liu, Yaoshan Dun, Baiyang You, Siqian Fu, Ning Xu, Jeffrey William Ripley-Gonzalez, Ni Cui

“…Results revealed 110 and 71 relapses and deaths per 1000 person-years for patients with FEV1 values of <82%pred and ≥82%pred, respectively. …”
Get full text

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive... by Zhiwei Chen, Jianhua Chen, Dingzhi Huang, Wei Zhang, Lin Wu, Tienan Yi, Qiming Wang, Liang Han, Liping Tan, Yinyin Li, Zhihong Zhang, Na Li, Jie li, Tongmei Zhang, Ying Hu, Hongmei Sun, Youhua Wu, Zhiyong He, Runxiang Yang, Peng Cheng, Xingya Li, Jianhua Shi, Guohua Yu, Daiyuan Ma, Benjamin Xiaoyi Li, Xiangrong Dai, Michael Wong, Yujie Li, Xiaohui Yu, Shun Lu, for the Socazolimab Study Group

“…As of October 13, 2023, patients treated with socazolimab presented significant overall survival (OS) benefit (13.90 months) compared with the placebo plus EC group (11.58 months) (hazard ratio for death, 0.799; 95% CI, 0.652–0.979; p = 0.0158). The median progression free survival (PFS) was 5.55 months in the socazolimab plus EC group, prolonging disease progression or death by nearly 1.2 months (5.55 months vs 4.37 months, hazard ratio for progression or death, 0.569; 95% CI, 0.457–0.708; p < 0.0001). 200 (80.3%) patients in the socazolimab plus EC group experienced ≥ grade 3 treatment-related adverse events and 187 (75.7%) patients occurred in the placebo plus EC group. …”
Get full text

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung canc... by Ke Wang, Ke Wang, Chuangjie Zheng, Chuangjie Zheng, Xinrong Chen, Xinrong Chen, Penghui Lin, Mengge Lin, Cuizhen Chen, Linzhu Zhai

“…ObjectiveTo compare the efficacy and safety of programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) and programmed cell death ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) for the treatment of extensive-stage small-cell lung cancer (ES-SCLC).MethodsWe performed a meta-analysis of relevant data using R software, considering overall survival (OS), progression-free survival (PFS), and grade ≥ 3 treatment-related adverse events (TRAES).ResultsPD-1 + Chemo (OS: hazard ratio [HR] 0.71; PFS: HR 0.59) and PD-L1 + Chemo (OS: HR 0.72; PFS: HR 0.73) significantly prolonged survival and did not increase the incidence of grade ≥3 TRAEs compared with chemotherapy. …”
Get full text

Contribution of cuproptosis and immune-related genes to idiopathic pulmonary fibrosis disease by Chengji Jin, Jia Li, Qiaoyu Li, Lipeng Zhang, Shaomao Zheng, Qiong Feng, Yongjie Li, Yu Zheng, Qiuli Nie, Jin Liang, Jing Wang, Jing Wang

“…Cuproptosis, a novel form of copper-induced cell death, has garnered attention for its potential implications. …”
Get full text

The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer by Hao Luo, Bin Hu, Xiang-Rong Gu, Jing Chen, Xiao-Qing Fan, Wei Zhang, Ren-Tao Wang, Xian-Dong He, Wei Guo, Nan Dai, Dan Jian, Qing Li, Cheng-Xiong Xu, Hua Jin

“…Abstract Programmed cell death protein ligand-1 (PD-L1) and major histocompatibility complex I (MHC-I) are key molecules related to tumor immune evasion and resistance to programmed cell death protein 1 (PD-1)/PD-L1 blockade. …”
Get full text

Thioredoxin‐interacting protein (TXNIP) is a substrate of the NEDD4‐like E3 ubiquitin‐protein ligase WWP1 in cellular redox state regulation of acute myeloid leukemia cells by Sara Giovannini, Yanan Li, Rosalba Pecorari, Claudia Fierro, Claudia Fiorilli, Federica Corigliano, Valeria Moriconi, Ji Zhou, Anna De Antoni, Artem Smirnov, Sara Rinalducci, Anna Maria Timperio, Massimiliano Agostini, Jinping Zhang, Yufang Shi, Eleonora Candi, Gerry Melino, Francesca Bernassola

“…The HECT‐type E3 ubiquitin WWP1 (also known as NEDD4‐like E3 ubiquitin‐protein ligase WWP1) acts as an oncogenic factor in acute myeloid leukemia (AML) cells. WWP1 overexpression in AML confers a proliferative advantage to leukemic blasts (abnormal immature white blood cells) and counteracts apoptotic cell death and differentiation. …”
Get full text

The endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 3 attenuates the unfolded protein response and has pro-survival and pro-viral roles in hepatoma cells and... by Alina-Veronica Ghionescu, Mihaela Uta, Andrei Sorop, Catalin Lazar, Petruta R. Flintoaca-Alexandru, Gabriela Chiritoiu, Livia Sima, Stefana-Maria Petrescu, Simona Olimpia Dima, Norica Branza-Nichita

“…Conversely, cell depletion of EDEM3 resulted in significant ER stress inducing pro-apoptotic mechanisms and cell death. …”
Get full text

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses... by Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen

“…Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.Methods and analysis Progression-free survival (PFS), overall survival (OS) and objective response per baseline NER were analysed in the overall population and in patients with programmed death ligand 1 (PD-L1+) tumours. …”
Get full text

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature by Guangjian Yang, Linyan Tian, Yan Wang

“…Abstract Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with chemotherapy. …”
Get full text

Molecular Insights in the Anticancer Activity of Natural Tocotrienols: Targeting Mitochondrial Metabolism and Cellular Redox Homeostasis by Raffaella Chiaramonte, Giulia Sauro, Domenica Giannandrea, Patrizia Limonta, Lavinia Casati

“…Mitochondria are also the primary source of intracellular ROS. Cancer cells maintain moderate levels of ROS to promote tumorigenesis, metastasis, and drug resistance; indeed, once the cytotoxicity threshold is exceeded, ROS trigger oxidative damage, ultimately leading to cell death. …”
Get full text

Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B... by Runhui Zheng, Xiaobo Chen, Chunyan Wang, Pengfei Qin, Huo Tan, Xiaodan Luo

“…We report a case with “double-expressor” DLBCL treated with a combined regimen which consisted of programmed cell death protein 1 (PD-1) inhibitor, DNA methyltransferase inhibitor (DNMTi), and histone deacetylase inhibitor (HDACi). …”
Get full text

Hydrolase-Treated Royal Jelly Attenuates H2O2- and Glutamate-Induced SH-SY5Y Cell Damage and Promotes Cognitive Enhancement in a Rat Model of Vascular Dementia by Nualpun Sirinupong, Worrapanitch Chansuwan, Pratchaya Kaewkaen

“…The results showed that RJH has no cytotoxic effect with the final concentration up to 500 μg protein/ml and reduces cell death from the H2O2- and glutamate-induced cell damage in in vitro neuroblastoma cells. …”
Get full text

Cryoimmobilized anther analysis reveals new ultrastructural insights into Rhynchospora (Cyperaceae) asymmetrical microsporogenesis by Danilo M. Rocha, Ulla Neumann, Fernanda M. Nogueira, Georgios Tsipas, André L. L. Vanzela, André Marques

“…IntroductionThe Cyperaceae family is distinguished by holocentric chromosomes and a distinctive microsporogenesis process, which includes inverted meiosis, asymmetric tetrad formation, selective cell death, and the formation of pseudomonad pollen. …”
Get full text

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and n... by Linfeng Wang, Guangda Zheng, Yue Hu, Ayidana Maolan, Yue Luo, Yue Li, Rui Liu

“…Results We analyzed nine studies involving 3431 patients, including eight perioperative neoadjuvant immunotherapy combinations for non-small cell lung cancer. For patients without programmed death-ligand 1(PD-L1) selection, Toripalimab plus chemotherapy provided the best Pathological complete response (PCR) benefit (OR = 32.89,95% CI:7.88-137.32), best Major Pathological response (MPR) benefit (OR = 10.25, 95% CI: 5.81–18.10) and best Event-free survival (EFS) benefit (HR = 0.40,95% CI: 0.28–0.57). …”
Get full text

Association between red cell distribution width to albumin ratio and all-cause mortality in patients with acute pancreatitis admitted to the intensive care unit: a retrospective st... by Xuan Chen, Yuchen Luo, Side Liu

“…BackgroundRed blood cell volume distribution width (RDW) and albumin (Alb) have been proved to be predictors of mortality in various diseases, such as acute pancreatitis (AP). …”
Get full text

Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients by Tara Seery, Lennie Sender, Omid Jafari, Frank Jones, Patricia Spilman, Sandeep B. Reddy, Patrick Soon-Shiong

“…Induction of immunogenic cell death (ICD) by use of relatively low-dose chemo- or radiation therapy, enhancement of immune responses by the IL-15 superagonist N-803 (Anktiva®), and targeting of programmed death receptor ligand 1 (PD-L1)-expressing cells may offer a therapeutic approach to refractory mPC with the potential to increase overall survival (OS).MethodsFrom late 2019 to 2021, single-patient Investigational New Drug (spIND) protocols for five mPC patients were designed and approved that generally comprised combined Abraxane (nab-paclitaxel) and gemcitabine therapy with experimental therapeutics N-803, PD-L1-targeted high-affinity natural killer (PD-L1 t-haNK) cells, and aldoxorubicin, a serum albumin-binding doxorubicin prodrug. …”
Get full text